Lorvotuzumab
Based on 1 Customer Validation
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.77%
- CAS No.: 339306-30-8
- Masse moléculaire:146.44 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Human IgG1 kappa
Human
NCAM1/CD56
Lorvotuzumab mertansine (IMGN901) is an ADC that links a potent anti-mitotic (DM1) via a disulfide linker to CD56 targeting antibodies (Lorvotuzumab). Lorvotuzumab mertansine against Wilms tumor, rhabdomyosarcoma, and neuroblastoma[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized NCAM-1/CD56 Protein, Human (HEK293, His, solution, HY-P75933) can bind Lorvotuzumab. The EC50 for this effect is 56.21 ng/mL. -
Loaded Lorvotuzumab on AHC2 biosensor, can bind NCAM-1/CD56 Protein, Human (HEK293, His-Avi, HY-P75932) with an affinity constant of 3.918E-09 M as determined in BLI assay. -
Flow Cytometry analysis of SK-N-SH cells with NCAM1/CD56 (red) with Lorvotuzumab (anti-NCAM1/CD56) (HY-P99372). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 339306-30-8
-
Appearance Liquid
-
Masse moléculaire 146.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Lorvotuzumab]
-
Synonyms
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)